Award
NIH Reporter #5U01NS123252-05
Antiglutamatergic Therapy to Protect the Brain Against Nerve Agents
Recipient
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD
Award Amount
$717,817.00
Ceiling
$717,817.00
Awarded
August 26, 2026
Identifier
5U01NS123252-05
Research project to develop and test a combination therapy for neuroprotection against nerve agents using rat models, focusing on seizure control and neuronal damage prevention.
Description
This project aims to develop and test antiglutamatergic therapy for neuroprotection against nerve agents. The therapy involves LY293558, an AMPA/GluK1 receptor antagonist, and caramiphen, an antimuscarinic that also antagonizes NMDA receptors. The research will evaluate the efficacy of this combination in controlling seizures, preventing neuronal damage, and reducing behavioral abnormalities in adult and aged rats exposed to soman, a nerve agent.